Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1989 Jul;97(3):769–776. doi: 10.1111/j.1476-5381.1989.tb12015.x

Kappa-opioid-induced changes in renal water and electrolyte management and endocrine secretion.

N Ashton 1, R J Balment 1, T P Blackburn 1
PMCID: PMC1854587  PMID: 2547485

Abstract

1. Subcutaneous injection of the kappa-opioid agonist U50,488 into conscious, saline-loaded rats was associated with a diuresis, antinatriuresis and antikaliuresis which lasted for up to 3 h. Plasma renin activity and corticosterone levels were elevated but plasma vasopressin (AVP) and aldosterone levels were unaltered in similarly treated rats. 2. U50,488 administration to adrenal demeddulated rats was not associated with a diuresis but produced an antinatriuresis, though sodium excretion rates were higher in demedullated than in sham-operated animals. Plasma AVP and corticosterone levels were not affected by demeddulation or subsequent U50,488 treatment. Sham-operated, U50-488-treated rats showed the expected increase in plasma corticosterone levels. 3. U50,488 administration resulted in an antidiuresis and an antinatriuresis in AVP-deficient Brattleboro DI rats. 4. When coupled with fasting stress U50,488 administration resulted in similar but attenuated renal responses compared with those observed in unfasted rats. Basal plasma corticosterone levels were elevated in fasted animals and were further increased by U50,488. 5. Both water and electrolyte handling by the kidney are altered by U50,488. The diuretic effects of U50,488 were reversed by adrenal demedullation and in the absence of endogenous AVP, but the antinatriuretic actions were not altered, suggesting that the effects upon renal water and electrolyte excretion may be mediated by separate mechanisms.

Full text

PDF
769

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ang V. T., Jenkins J. S. Neurohypophysial hormones in the adrenal medulla. J Clin Endocrinol Metab. 1984 Apr;58(4):688–691. doi: 10.1210/jcem-58-4-688. [DOI] [PubMed] [Google Scholar]
  2. Ashton N., Balment R. J. Blood pressure and renal function in a novel vasopressin-deficient, genetically hypertensive rat strain. J Physiol. 1989 Mar;410:21–34. doi: 10.1113/jphysiol.1989.sp017518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Blackburn T. P., Borkowski K. R., Friend J., Rance M. J. On the mechanisms of kappa-opioid-induced diuresis. Br J Pharmacol. 1986 Nov;89(3):593–598. doi: 10.1111/j.1476-5381.1986.tb11160.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Borkowski K. R., Quinn P. The effect of bilateral adrenal demedullation on vascular reactivity and blood pressure in spontaneously hypertensive rats. Br J Pharmacol. 1983 Nov;80(3):429–437. doi: 10.1111/j.1476-5381.1983.tb10712.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Eisenberg R. M. Plasma corticosterone changes in response to central or peripheral administration of kappa and sigma opiate agonists. J Pharmacol Exp Ther. 1985 Jun;233(3):863–869. [PubMed] [Google Scholar]
  6. Fuller R. W., Leander J. D. Elevation of serum corticosterone in rats by bremazocine, a kappa-opioid agonist. J Pharm Pharmacol. 1984 May;36(5):345–346. doi: 10.1111/j.2042-7158.1984.tb04392.x. [DOI] [PubMed] [Google Scholar]
  7. Huidobro-Toro J. P. Antidiuretic effect of beta-endorphin and morphine in Brattleboro rats: development of tolerance and physical dependence after chronic morphine treatment. Br J Pharmacol. 1980;71(1):51–56. doi: 10.1111/j.1476-5381.1980.tb10908.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Huidobro-Toro J. P., Parada S. Kappa-opiates and urination: pharmacological evidence for an endogenous role of the kappa-opiate receptor in fluid and electrolyte balance. Eur J Pharmacol. 1984 Dec 15;107(1):1–10. doi: 10.1016/0014-2999(84)90084-0. [DOI] [PubMed] [Google Scholar]
  9. Iyengar S., Kim H. S., Wood P. L. Kappa opiate agonists modulate the hypothalamic-pituitary-adrenocortical axis in the rat. J Pharmacol Exp Ther. 1986 Aug;238(2):429–436. [PubMed] [Google Scholar]
  10. Kime D. E. Measurement of 1alpha-hydroxycorticosterone and other corticosteroids in elasmobranch plasma by radioimmunoassay. Gen Comp Endocrinol. 1977 Nov;33(3):344–351. doi: 10.1016/0016-6480(77)90049-1. [DOI] [PubMed] [Google Scholar]
  11. Lahti R. A., Collins R. J. Opiate effects on plasma corticosteroids: relationship to dysphoria and self-administration. Pharmacol Biochem Behav. 1982 Jul;17(1):107–109. doi: 10.1016/0091-3057(82)90270-2. [DOI] [PubMed] [Google Scholar]
  12. Leander J. D. A kappa opioid effect: increased urination in the rat. J Pharmacol Exp Ther. 1983 Jan;224(1):89–94. [PubMed] [Google Scholar]
  13. Leander J. D. Further study of kappa opioids on increased urination. J Pharmacol Exp Ther. 1983 Oct;227(1):35–41. [PubMed] [Google Scholar]
  14. Leander J. D., Zerbe R. L., Hart J. C. Diuresis and suppression of vasopressin by kappa opioids: comparison with mu and delta opioids and clonidine. J Pharmacol Exp Ther. 1985 Aug;234(2):463–469. [PubMed] [Google Scholar]
  15. Miller M. Inhibition of ADH release in the rat by narcotic antagonists. Neuroendocrinology. 1975;19(3):241–251. doi: 10.1159/000122444. [DOI] [PubMed] [Google Scholar]
  16. Milne C. M., Balment R. J., Henderson I. W., Mosley W., Jones I. C. Adrenocortical function in the Brattleboro rat. Ann N Y Acad Sci. 1982;394:230–240. doi: 10.1111/j.1749-6632.1982.tb37431.x. [DOI] [PubMed] [Google Scholar]
  17. Oldham A. A., Arnstein M. J., Major J. S., Clough D. P. In vivo comparison of the renin inhibitor H77 with the angiotensin-converting enzyme inhibitor captopril. J Cardiovasc Pharmacol. 1984 Jul-Aug;6(4):672–677. doi: 10.1097/00005344-198407000-00019. [DOI] [PubMed] [Google Scholar]
  18. Quirion R., Finkel M. S., Mendelsohn F. A., Zamir N. Localization of opiate binding sites in kidney and adrenal gland of the rat. Life Sci. 1983;33 (Suppl 1):299–302. doi: 10.1016/0024-3205(83)90502-7. [DOI] [PubMed] [Google Scholar]
  19. Slizgi G. R., Ludens J. H. Displacement of 3H-EKC binding by opioids in rat kidney: a correlate to diuretic activity. Life Sci. 1985 Jun 10;36(23):2189–2193. doi: 10.1016/0024-3205(85)90328-5. [DOI] [PubMed] [Google Scholar]
  20. Slizgi G. R., Ludens J. H. Studies on the nature and mechanism of the diuretic activity of the opioid analgesic ethylketocyclazocine. J Pharmacol Exp Ther. 1982 Mar;220(3):585–591. [PubMed] [Google Scholar]
  21. Slizgi G. R., Taylor C. J., Ludens J. H. Effects of the highly selective kappa opioid, U-50, 488, on renal function in the anesthetized dog. J Pharmacol Exp Ther. 1984 Sep;230(3):641–645. [PubMed] [Google Scholar]
  22. Vonvoigtlander P. F., Lahti R. A., Ludens J. H. U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist. J Pharmacol Exp Ther. 1983 Jan;224(1):7–12. [PubMed] [Google Scholar]
  23. Xie C. W., Yin L. Y., Xie X. Z., Gao X. M., Xia Z. Q., Chang J. K., Tang J. A dynorphin peptide induces hypotension by stimulating the release of atrial natriuretic peptide from rat atrium. Life Sci. 1988;42(11):1117–1122. doi: 10.1016/0024-3205(88)90605-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES